U01 CA141541/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2011	2
2012	6
2013	5
2014	7
2015	8
2016	2
2017	1
2018	1
2019	1
2022	0

1

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL. Chang CH, et al. Cell. 2015 Sep 10;162(6):1229-41. doi: 10.1016/j.cell.2015.08.016. Epub 2015 Aug 27. Cell. 2015. PMID: 26321679 Free PMC article.

2

Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity.

Alspach E, Lussier DM, Schreiber RD. Alspach E, et al. Cold Spring Harb Perspect Biol. 2019 Mar 1;11(3):a028480. doi: 10.1101/cshperspect.a028480. Cold Spring Harb Perspect Biol. 2019. PMID: 29661791 Free PMC article. Review.

3

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

Mittal D, Gubin MM, Schreiber RD, Smyth MJ. Mittal D, et al. Curr Opin Immunol. 2014 Apr;27:16-25. doi: 10.1016/j.coi.2014.01.004. Epub 2014 Feb 14. Curr Opin Immunol. 2014. PMID: 24531241 Free PMC article. Review.

4

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Gubin MM, et al. Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988. Nature. 2014. PMID: 25428507 Free PMC article.

5

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.

Vesely MD, Schreiber RD. Vesely MD, et al. Ann N Y Acad Sci. 2013 May;1284(1):1-5. doi: 10.1111/nyas.12105. Ann N Y Acad Sci. 2013. PMID: 23651186 Free PMC article.

6

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.

Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Matsushita H, et al. Nature. 2012 Feb 8;482(7385):400-4. doi: 10.1038/nature10755. Nature. 2012. PMID: 22318521 Free PMC article.

7

Aging Mouse Models Reveal Complex Tumor-Microenvironment Interactions in Cancer Progression.

Mori H, Cardiff RD, Borowsky AD. Mori H, et al. Front Cell Dev Biol. 2018 Mar 29;6:35. doi: 10.3389/fcell.2018.00035. eCollection 2018. Front Cell Dev Biol. 2018. PMID: 29651417 Free PMC article. Review.

8

Tumor neoantigens: building a framework for personalized cancer immunotherapy.

Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Gubin MM, et al. J Clin Invest. 2015 Sep;125(9):3413-21. doi: 10.1172/JCI80008. Epub 2015 Aug 10. J Clin Invest. 2015. PMID: 26258412 Free PMC article. Review.

9

Morphologic manifestations of gene-specific molecular alterations ("genetic addictions") in mouse models of disease.

Couto SS, Bolon B, Cardiff RD. Couto SS, et al. Vet Pathol. 2012 Jan;49(1):116-29. doi: 10.1177/0300985811430962. Epub 2011 Dec 14. Vet Pathol. 2012. PMID: 22173978 Review.

10

A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin.

Hou KK, Pan H, Schlesinger PH, Wickline SA. Hou KK, et al. Biotechnol Adv. 2015 Nov 1;33(6 Pt 1):931-40. doi: 10.1016/j.biotechadv.2015.05.005. Epub 2015 May 27. Biotechnol Adv. 2015. PMID: 26025036 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results